Clinical Topics & News

Pregnancy After Cervical Surgery: What Are the Risks?

Researchers studied the risk factors for having a healthy pregnancy after surgery


 

Surgeries for cervical intraepithelial neoplasia (CIN) have been linked to preterm birth, low birth weight, and pregnancy loss, among other adverse effects. But the mechanisms have not been entirely explained. Are the outcomes due to the surgery, the immunologic factors, or the risk factors associated with CIN?

Related: PAP Test/HPV Co-test: Quality Improvement Initiative to Identify Approaches for Integrative Clinical Care Management

The greater risk of pregnancy problems derives primarily from the treatment not from characteristics of human papillomavirus or CIN, say researchers from Kaiser Permanente Northwest, Duke University, and GlaxoSmithKline. They compared 322 women who had undergone excisional and ablative cervical surgery with 4,307 women who had not and with 847 women who had undergone only diagnostic procedures.

Of the treated women, 163 had a live birth within 1 year of treatment. Women who had undergone thick excisional cervical surgical procedures ( ≥ 1.0 cm) had approximately double the risk of preterm birth and low-birth-weight infants compared with that of the other 2 groups. The risk was higher if the baby was born within 1 year of surgery. The risk of cesarean delivery rose 20% with excisional surgery. The treated women did not have a substantially higher risk of dysfunctional labor.

Related: More Evidence of HPV’s Role in Cancer

Among the women who had cervical surgery, 21% lost the pregnancy (25% of those with ablative and 19% of those with excisional surgery). By contrast, 18% of the unexposed women and 20% of the diagnostic-only group experienced pregnancy loss. The researchers say the positive association between pregnancy loss and ablative surgical treatment has not been previously reported. “These findings suggest that efforts to minimize excision thickness in cervical surgeries are prudent,” the researchers advise.

Source:
Weinmann S, Naleway A, Swamy G, et al. PLoS One. 2017;12(1):e0165276.
doi: 10.1371/journal.pone.0165276.

Recommended Reading

Abstracts Presented at the 2016 AVAHO Annual Meeting
Federal Practitioner
Ototoxicity From Cisplatin: Who Is at Risk and Who May Benefit From Treatment?
Federal Practitioner
IHS Joins Forces With Cancer Center
Federal Practitioner
Long view shows doubling of survival in non-Hodgkin lymphoma
Federal Practitioner
Novel Treatment Shows Promise for Acute Lymphoblastic Leukemia
Federal Practitioner
Guidelines tackle long-term screening, management of myeloma
Federal Practitioner
Phase III trial: VZV protects auto-HCT patients
Federal Practitioner
The Availability of Advanced Radiation Oncology Technology Within VHA Radiation Oncology Centers
Federal Practitioner
γ-δ T-Cell Lymphoma With Disseminated Intravascular Coagulation and Autoimmune Hemolytic Anemia
Federal Practitioner
Best Practices in Hematology and Oncology (February 2017)
Federal Practitioner